Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
ANI Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
ANI Pharmaceuticals has a total shareholder equity of $480.6M and total debt of $285.2M, which brings its debt-to-equity ratio to 59.4%. Its total assets and total liabilities are $920.8M and $440.1M respectively. ANI Pharmaceuticals's EBIT is $48.2M making its interest coverage ratio 2.3. It has cash and short-term investments of $247.1M.
Anahtar bilgiler
59.4%
Borç/özkaynak oranı
US$285.24m
Borç
| Faiz karşılama oranı | 2.3x |
| Nakit | US$247.05m |
| Eşitlik | US$480.61m |
| Toplam yükümlülükler | US$440.14m |
| Toplam varlıklar | US$920.75m |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: BSFA's short term assets ($555.5M) exceed its short term liabilities ($140.0M).
Uzun Vadeli Yükümlülükler: BSFA's short term assets ($555.5M) exceed its long term liabilities ($300.2M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: BSFA's net debt to equity ratio (7.9%) is considered satisfactory.
Borcun Azaltılması: BSFA's debt to equity ratio has reduced from 92.5% to 59.4% over the past 5 years.
Borç Kapsamı: BSFA's debt is well covered by operating cash flow (39.5%).
Faiz Kapsamı: BSFA's interest payments on its debt are not well covered by EBIT (2.3x coverage).